Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Auld, Andrew F ^a   Mbofana, Francisco ^b   Shiraishi, Ray W ^a   Sanchez, Mauro ^a   Alfredo, Charity ^a   Nelson, Lisa J ^a   Ellerbrock, Tedd ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; MOZAMBIQUE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME; TUBERCULOSIS; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT FAILURE; WEIGHT GAIN;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; MOZAMBIQUE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; WEIGHT GAIN;

EID: 79953692391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018453     Document Type: Article

References (76)

1. World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector- Progress report (2010) Geneva, Switzerland: WHO; 2010. Avaliable: http://www.who.int/hiv/pub/2010progressreport/en/. Accessed 29 January 2011.
2. Boerma JT, Stanecki KA, Newell ML, Luo C, Beusenberg M, et al. (2006) Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ 84: 145-150.
3. Bennett S, Boerma JT, Brugha R, (2006) Scaling up HIV/AIDS evaluation. Lancet 367: 79-82.
4. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, et al. (2005) Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 38: 14-17.
5. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
6. Stringer J, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
7. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
8. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
9. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
10. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22: 873-882.
11. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
12. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20: 41-48.
13. Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, et al. (2009) Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 52: 49-55.
14. Multi-Sectoral Technical Group Support for the Fight Against HIV/AIDS in Mozambique. Impacto demografico do HIV/SIDA em Mozambique. Ministry of Health HIV/AIDS Website. Available: http://www.ine.gov.mz/hiv/ImpactoHIV.pdf. Accessed 29 January 29 2011.
15. World Health Organization. Towards universal access- scaling up priority HIV/AIDS interventions in the health sector, (2008) Geneva Switzerland: WHO; 2008. Accessed: http://www.who.int/hiv/pub/2008progressreport/en/. Accessed 29 January 2011.
16. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach 2006 revision. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 29 January 2011.
17. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151: 241-251.
18. Fox MP, Rosen S, (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15 (Suppl 1): 1-15.
19. Brentlinger PE, Torres JV, Martinez PM, Ghee A, Lujan J, et al. (2010) Clinical staging of HIV-related illness in Mozambique: performance of nonphysician clinicians based on direct observation of clinical care and implications for health worker training. J Acquir Immune Defic Syndr 55: 351-355.
20. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, et al. (2009) Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23: 1867-1874.
21. Fairley CK, Permana A, Read TR, (2005) Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med 6: 366-369.
22. Lucas GM, Chaisson RE, Moore RD, (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: 81-87.
23. Grossberg R, Zhang Y, Gross R, (2004) A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 57: 1107-1110.
24. Rubin DB, (1987) Multiple Imputation for Nonresponse in Surveys. New York J. Wiley & Sons.
25. Royston P, (2004) Multiple imputation of missing values. The Stata Journal 4 (3): 227-241.
26. Royston P, (2005) Multiple imputation of missing values: update. The Stata Journal 5 (2): 188-201.
27. Royston P, (2005) Multiple imputation of missing values: update of ice. The Stata Journal 5 (4): 527-536.
28. White IR, Royston P, (2009) Imputing missing covariate values for the Cox model. Stat Med 28: 1982-1998.
29. Grambsch PM, Therneau TM, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
30. Royston P, Carlin JB, White IR, (2009) Multiple imputation of missing values: new features for mim. The Stata Journal 9 (2): 252-264.
31. Raudenbush SW, Bryk AS, (2002) Hierarchical Linear Models: Applications and Data Analysis Methods. Newbury Park, California Sage.
32. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278-1286.
33. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, et al. (2007) Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 46: 56-61.
34. Alemu AW, Sebastian MS, (2010) Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action 3 doi:10.3402/gha.v3i0.5398.
35. Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, et al. (2010) Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 24: 1709-1716.
36. Crepaz N, Hart TA, Marks G, (2004) Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 292: 224-236.
37. Rosen S, Ketlhapile M, (2010) Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health 15 (Suppl 1): 98-104.
38. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 85: 550-554.
39. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2009) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
40. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN, (2008) Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 300: 506-507.
41. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 3: e1725.
42. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
43. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360: 34-40.
44. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, et al. (2003) Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 17 (Suppl 3): S5-15.
45. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, et al. (2003) Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 8: 385-393.
46. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, et al. (2005) Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336-343.
47. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43: 770-776.
48. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
49. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20: 2355-2360.
50. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, et al. (2007) Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis 11: 412-416.
51. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
52. Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, et al. (2007) Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 8: 8-16.
53. Sherr K, Pfeiffer J, Mussa A, Vio F, Gimbel S, et al. (2009) The role of nonphysician clinicians in the rapid expansion of HIV care in Mozambique. J Acquir Immune Defic Syndr 52 (Suppl 1): S20-23.
54. Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, et al. (2010) Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15: 251-258.
55. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
56. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, et al. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 2483-2491.
57. Jerene D, Endale A, Hailu Y, Lindtjorn B, (2006) Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis 6: 136.
58. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach- 2010 revision. Geneva, Switzerland: WHO; (2010) Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 29 January 2011.
59. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
60. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
61. Donovan C, Massingue J, (2007) Illness, death, and macronutrients: adequacy of rural Mozambican household production of macronutrients in the face of HIV/AIDS. Food Nutr Bull 28: S331-338.
62. Coyne-Meyers K, Trombley LE, (2004) A review of nutrition in human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Nutr Clin Pract 19: 340-355.
63. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, et al. (2009) Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 53: 4789-4793.
64. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, et al. (2008) Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 24: 555-560.
65. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
66. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563-572.
67. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86: 939-947.
68. Brinkhof MW, Pujades-Rodriguez M, Egger M, (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.
69. Allen S, Tice J, Van de Perre P, Serufilira A, Hudes E, et al. (1992) Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa. BMJ 304: 1605-1609.
70. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, et al. (2003) Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 17: 733-740.
71. Kamenga M, Ryder RW, Jingu M, Mbuyi N, Mbu L, et al. (1991) Evidence of marked sexual behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience at an HIV counselling center in Zaire. AIDS 5: 61-67.
72. United States Centers for Disease Control and Prevention (2003) Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. JAMA 289: 2493-2495.
73. Gordon CM, Stall R, Cheever LW, (2004) Prevention interventions with persons living with HIV/AIDS: challenges, progress, and research priorities. J Acquir Immune Defic Syndr 37 (Suppl 2): S53-57.
74. Gordon CM, Forsyth AD, Stall R, Cheever LW, (2005) Prevention interventions with persons living with HIV/AIDS: state of the science and future directions. AIDS Educ Prev 17: 6-20.
75. Janssen RS, Valdiserri RO, (2004) HIV prevention in the United States: increasing emphasis on working with those living with HIV. J Acquir Immune Defic Syndr 37 (Suppl 2): S119-121.
76. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. (2006) Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 20: 85-92.